Dr Reddy's signs royalty-free license with Gilead for lenacapavir
- Dr Reddy's signs voluntary royalty-free license with Gilead Sciences
- Deal covers investigational once-yearly lenacapavir for HIV prevention
- Agreement removes royalty barriers to expand therapy access
*this image is generated using AI for illustrative purposes only.
Dr Reddy's Laboratories has entered into a voluntary, royalty-free license agreement with Gilead Sciences for investigational once-yearly lenacapavir, a medicine used in HIV prevention.
Agreement details
The license grants Dr Reddy's rights to the annual lenacapavir formulation under a royalty-free arrangement with Gilead Sciences. Lenacapavir is an antiretroviral agent used for HIV prevention, and the agreement positions Dr Reddy's to participate in its supply.
| Parameter | Details |
|---|---|
| Agreement type | Voluntary royalty-free license |
| Licensor | Gilead Sciences |
| Licensee | Dr Reddy's Laboratories |
| Product | Investigational once-yearly lenacapavir |
| Therapeutic area | HIV prevention |
Significance for HIV prevention access
The royalty-free structure of the agreement removes licensing cost barriers typically associated with patented medicines, which can be a significant factor in expanding access to HIV prevention therapies. Dr Reddy's, as a licensee, would be enabled to manufacture and supply lenacapavir without royalty obligations to Gilead Sciences.
How might this royalty-free licensing model influence Gilead's future intellectual property strategies for other high-demand therapeutics?
What is the projected timeline for Dr Reddy's to achieve commercial-scale manufacturing and distribution of lenacapavir in emerging markets?
Will this agreement accelerate the inclusion of long-acting HIV prevention options in WHO prequalification and national procurement lists?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
